Switzerland
· Delayed Price · Currency is CHF Idorsia Company Description
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland.
The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.
Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant) for the treatment of adult patients with insomnia.
The company has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and commercialize PIVLAZ.
It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy.
The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
| Country | Switzerland |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 650 |
| CEO | Jean-Paul Clozel |
Contact Details
Address: Hegenheimermattweg 91 Allschwil, 4123 Switzerland | |
| Phone | 41 58 844 10 10 |
| Website | idorsia.com |
Stock Details
| Ticker Symbol | IDIA |
| Exchange | SIX Swiss Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| ISIN Number | CH0363463438 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Andre C. Muller | Executive Vice President and Chief Financial Officer |
| Dr. Martine Clozel | Executive Vice President and Chief Scientific Officer |
| Dr. Guy Braunstein M.D. | Executive Vice President and Chief Medical Officer |
| Alberto Gimona M.D. | Executive Vice President and Head of Global Clinical Development |
| Julien Gander L.L.M. | Senior Vice President, Group General Counsel and Company Secretary |
| Alexander Khatuntsev | Senior Vice President and Head of Global Human Resources |
| Olivier Lambert | Senior Vice President and Head of Technical Operations |
| Markus A. Riederer | Senior Vice President and Head of Drug Discovery Biology |
| Christoph Boss | Senior Vice President and Head of Drug Discovery Chemistry |